Abstract
Introduction
We sought to determine whether loss of renal function increases risk of recurrence
and metastases in renal cell carcinoma (RCC), and whether this impact was age-related.
Materials and Methods
We performed a retrospective analysis of the International Marker Consortium for Renal
Cancer (INMARC) registry. Patients were separated into younger (<65 years old) and
elder (≥65 years old) age groups, and rates of de novo estimated glomerular filtration
rate (eGFR<45 mL/min/1.73m2 [eGFR<45]) were calculated. Multivariable analysis (MVA)
was conducted for predictors of progression-free survival (PFS) and all-cause mortality
(ACM). Kaplan-Meier Analysis (KMA) was conducted for PFS and overall survival (OS)
in younger and elder age groups stratified by functional status.
Results
We analyzed 1805 patients (1113 age<65, 692 age≥65). On MVA in patients <65, de novo
eGFR<45 was independently associated with greater risk for worsened progression (HR=1.61,
P=.038) and ACM (HR=1.82, P=.018). For patients ≥65, de novo eGFR<45 was not independently associated with progression
(P=.736), or ACM (P=.286). Comparing patients with de novo eGFR<45 vs. eGFR ≥45, KMA demonstrated worsened
5-year PFS and OS in patients <65 (PFS: 68% vs. 86%, P<.001; OS: 73% vs. 90%, P<.001), while in patients ≥65, only 5-year OS was worsened (77% vs. 81%, P<.021).
Conclusion
Development of de novo eGFR<45 was associated with more profound impact on patients
<65 compared to patients ≥65, being an independent risk factor for PFS and ACM. The
mechanisms of this phenomenon are unclear but underscore desirability for nephron
preservation when safe and feasible in younger patients.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical Genitourinary CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries published correction appears in.CA Cancer J Clin. 2020; 70: 313https://doi.org/10.3322/caac.21492
- Epidemiology of renal cell carcinoma.World J Oncol. 2020; 11: 79-87https://doi.org/10.14740/wjon1279
- Metabolic features of clear-cell renal cell carcinoma: mechanisms and clinical implications.Can Urol Assoc J. 2011; 5: 274-282https://doi.org/10.5489/cuaj.10196
- Go AS. CKD and the risk of incident cancer.J Am Soc Nephrol. 2014; 25: 2327-2334https://doi.org/10.1681/ASN.2013060604
- Renal cell carcinoma.Cancer Biomark. 2010; 9: 461-473https://doi.org/10.3233/CBM-2011-0176
- Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA: Cancer J Clin. 2021; 71: 209-249https://doi.org/10.3322/caac.21660
- Renal mass and localized renal cancer: evaluation, management, and follow-up: AUA guideline: part I.J Urol. 2021; 206 (-08): 199https://doi.org/10.1097/JU.0000000000001911
- Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study.Lancet Oncol. 2006; 7: 735-740https://doi.org/10.1016/S1470-2045(06)70803-8
- Comparison of rates and risk factors for developing chronic renal insufficiency, proteinuria and metabolic acidosis after radical or partial nephrectomy.BJU Int. 2009; 104: 476-481https://doi.org/10.1111/j.1464-410X.2009.08376.x
- Partial nephrectomy versus radical nephrectomy for clinical t1b and t2 renal tumors: a systematic review and meta-analysis of comparative studies.Eur Urol. 2017; 71: 606-617https://doi.org/10.1016/j.eururo.2016.08.060
- Laparoscopic radical versus partial nephrectomy for tumors >4 cm: intermediate-term oncologic and functional outcomes.Urology. 2009; 73: 1077-1082https://doi.org/10.1016/j.urology.2008.11.059
- Impact of worsening surgically induced chronic kidney disease (CKD-S) in preoperative CKD-naïve patients on survival in renal cell carcinoma.BJU Int. 2022; https://doi.org/10.1111/bju.15861
- Survival and functional stability in chronic kidney disease due to surgical removal of nephrons: importance of the new baseline glomerular filtration rate.Eur Urol. 2015; 68: 996-1003https://doi.org/10.1016/j.eururo.2015.04.043
- Effect of baseline glomerular filtration rate on survival in patients undergoing partial or radical nephrectomy for renal cortical tumors.Mayo Clin Proc. 2008; 83: 1101-1106https://doi.org/10.4065/83.10.1101
- Elevated preoperative C-reactive protein is associated with renal functional decline and non-cancer mortality in surgically treated renal cell carcinoma: analysis from the INternational Marker Consortium for Renal Cancer (INMARC).BJU Int. 2021; 127: 311-317https://doi.org/10.1111/bju.15200
- Preoperative elevation of c-reactive protein is a predictor for adverse oncologic survival outcomes for renal cell carcinoma: Analysis from the International Marker Consortium Renal Cancer (INMARC).Clin Genitourin Cancer. 2021; 19: e206-e215https://doi.org/10.1016/j.clgc.2021.02.003
- Updates in the eighth edition of the tumor-node-metastasis staging classification for urologic cancers.Eur Urol. 2018; 73: 560-569https://doi.org/10.1016/j.eururo.2017.12.018
- A new equation to estimate glomerular filtration rate published correction appears in.Ann Intern Med. 2011; 155: 408https://doi.org/10.7326/0003-4819-150-9-200905050-00006
- Below safety limits, every unit of glomerular filtration rate counts: assessing the relationship between renal function and cancer-specific mortality in renal cell carcinoma.Eur Urol. 2018; 74: 661-667https://doi.org/10.1016/j.eururo.2018.07.029
- Renal function impairment below safety limits correlates with cancer-specific mortality in localized renal cell carcinoma: results from a single-center study.Clin Genitourin Cancer. 2020; 18: e360-e367https://doi.org/10.1016/j.clgc.2019.12.005
- Does reduced renal function predispose to cancer-specific mortality from renal cell carcinoma?.Eur Urol. 2021; 79: 774-780https://doi.org/10.1016/j.eururo.2021.02.035
- Reduced estimated GFR and cancer mortality.Am J Kidney Dis. 2014; 63: 23-30https://doi.org/10.1053/j.ajkd.2013.07.008
- Analysis of survival for patients with chronic kidney disease primarily related to renal cancer surgery.BJU Int. 2018; 121: 93-100https://doi.org/10.1111/bju.13994
- Partial nephrectomy versus radical nephrectomy in patients with small renal tumors—is there a difference in mortality and cardiovascular outcomes?.J Urol. 2009; 181: 55-62https://doi.org/10.1016/j.juro.2008.09.017
- Comparison of partial vs radical nephrectomy with regard to other-cause mortality in T1 renal cell carcinoma among patients aged ≥75 years with multiple comorbidities.BJU Int. 2013; 111: 67-73https://doi.org/10.1111/j.1464-410X.2012.11254.x
- Partial nephrectomy is not associated with an overall survival advantage over radical nephrectomy in elderly patients with stage Ib-II renal masses: An analysis of the national cancer data base.Cancer. 2018; 124: 3839-3848https://doi.org/10.1002/cncr.31582
- Partial versus radical nephrectomy in very elderly patients: a propensity score analysis of surgical, functional and oncologic outcomes (RESURGE project).World J Urol. 2020; 38: 151-158https://doi.org/10.1007/s00345-019-02665-2
- Collaborative review of risk benefit trade-offs between partial and radical nephrectomy in the management of anatomically complex renal masses.Eur Urol. 2017; 72: 64-75https://doi.org/10.1016/j.eururo.2016.11.038
- C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: a European study of 313 patients.Cancer. 2007; 110: 1241-1247https://doi.org/10.1002/cncr.22896
- Preoperative neutrophil-lymphocyte ratio predicts death among patients with localized clear cell renal carcinoma undergoing nephrectomy.Urol Oncol. 2014; 32: 1277-1284https://doi.org/10.1016/j.urolonc.2014.05.014
- Platelet-lymphocyte ratio acts as an independent predictor of prognosis in patients with renal cell carcinoma.Clin Chim Acta. 2018; 480: 166-172https://doi.org/10.1016/j.cca.2018.02.014
Article info
Publication history
Published online: December 06, 2022
Accepted:
December 4,
2022
Received in revised form:
December 3,
2022
Received:
September 16,
2022
Publication stage
In Press Journal Pre-ProofIdentification
Copyright
© 2022 Published by Elsevier Inc.
